HHS inspector general to examine drug price issues
The HHS Office of Inspector General plans to examine a variety of issues related to drug prices and potential waste of medicines. Among the issues the OIG will address are unexplained price jumps, use of wasteful single vials for cancer treatments, tying rebates under Medicare Part D to inflation, and billing practices for compounded topical treatments.
STAT (11/10)